A Phase 2 interventional study of Fulvestrant and Fulvestrant in Advanced Breast Cancer and Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 35 sites in Japan. Open to female participants. Per ClinicalTrials.gov, last updated 2012-02-15.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.
Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 36th largest by enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2006, is one of 59 in phase 2, and was the 20th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–80 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
University of California, Irvine · Sites in United States
Ages 18+
Prof. Wolfgang Janni · Sites in Germany, Switzerland
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, fulvestrant is the treatment under test here. Read study by study →
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 63 · Phase 3 21 · Phase 4 4
First in 1997; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 71 across the 94 interventional studies. Of the 55 that completed or were terminated, 34 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 95 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 65th largest by enrollment of the 125 interventional ones that give a count, is one of 9 that started in 2006, is one of 31 in phase 2, and was the 27th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
7 of the studies testing fulvestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT00585507Beth Israel Deaconess Medical CenterEfficacy and Safety of 500mg of Fulvestrant | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 95 studies testing fulvestrant in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fulvestrant 250 mg intramuscular injection
Drug: Fulvestrant
Fulvestrant 250mg (Plus 250mg Loading Regimen)
Drug: Fulvestrant
Fulvestrant 500 mg
Drug: Fulvestrant
250 intramuscular injection
Also known as: Faslodex, ZD9238
500 mg intramuscular injection
Objective Response Rate (ORR)
An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. ORR is defined as percentage of patients with objective response. Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization
Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008)
Time to Progression (TTP)
Time (in days) from randomization until objective disease progression or death (in the absence of objective progression). RECIST tumour assessments carried out every 12 weeks from randomization (+/- 2 weeks) until data cut-off on 19th March 2008.
Time frame: every 12 weeks from randomization (+/- 2 weeks) until data cut-off (19th march 2008)
Duration of Response (DoR)
Time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who achieved a confirmed Complete Response or confirmed Partial Response.
Time frame: RECIST tumour assessments carried out every 12 weeks from randomisation (+/- 2 weeks) until data cut-off on19th March 2008.
Clinical Benefit Rate (CBR)
A Clinical Benefit (CB) responder is defined as a patient having a best overall response of Complete response (CR), Partial Response (PR) or Stable disease (SD) provided SD (or better) was present = 154 days from randomization (ie SD = 24 weeks with the 2 week RECIST assessment time window allowed). The Clinical Benefit Rate is the percentage of patients with CB.
Time frame: every 12 weeks(+/- 2 weeks) from randomization to data up to data cut-off, 19th March 2008.
Pharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body
The measure of dispersion for mean population clearance is based on the estimated inter-individual variance
Time frame: Baseline to 12 weeks
Pharmacokinetic Parameter: Mean Volume of Distribution at Steady State, a Measure of the Apparent Volume in the Body Into Which Fulvestrant Distributes
The measure of dispersion for volume of distribution is based on the inter-individual variance estimated for the apparent volume of plasma into which Fulvestrant distributes
Time frame: Baseline to 12 weeks
Postmenopausal women with oestrogen receptor positive advanced breast cancer progressing or relapsing after previousendocrine therapy were randomized between 7th March 2006 and 4th September 2007. The trial was conducted in Japan only. One patient randomised to Fulvestrant 500mg was not dosed, so the Safety population has 46 patients for that arm.
| Milestone | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Started | 45 | 51 | 47 |
| Completed | 14 | 17 | 14 |
| Not completed | 31 | 34 | 33 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Disease progression | 27 | 31 | 28 |
| Withdrew: Subjective disease progression | 1 | 2 | 2 |
| Withdrew: Tumor marker elevation | 0 | 0 | 1 |
An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. ORR is defined as percentage of patients with objective response. Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization
| percentage of participants | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Objective Response Rate (ORR) | 11.1 | 17.6 | 10.6 |
Time (in days) from randomization until objective disease progression or death (in the absence of objective progression). RECIST tumour assessments carried out every 12 weeks from randomization (+/- 2 weeks) until data cut-off on 19th March 2008.
| days | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Time to Progression (TTP) | 169 (30 to 508) | 211 (0 to 426) | 169 (0 to 590) |
Time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who achieved a confirmed Complete Response or confirmed Partial Response.
Results for this outcome have not been posted.
A Clinical Benefit (CB) responder is defined as a patient having a best overall response of Complete response (CR), Partial Response (PR) or Stable disease (SD) provided SD (or better) was present = 154 days from randomization (ie SD = 24 weeks with the 2 week RECIST assessment time window allowed). The Clinical Benefit Rate is the percentage of patients with CB.
| percentage of participants | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Clinical Benefit Rate (CBR) | 42.2 | 54.9 | 46.8 |
The measure of dispersion for mean population clearance is based on the estimated inter-individual variance
| L/h | Fulvestrant |
|---|---|
| Pharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body | 34.4 ± 0.096 |
The measure of dispersion for volume of distribution is based on the inter-individual variance estimated for the apparent volume of plasma into which Fulvestrant distributes
| Vss/F (L) | Fulvestrant |
|---|---|
| Pharmacokinetic Parameter: Mean Volume of Distribution at Steady State, a Measure of the Apparent Volume in the Body Into Which Fulvestrant Distributes | 35300 ± 0.175 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fulvestrant 250 mg | — | 2/45 (4.4%) | 44/45 (97.8%) |
| Fulvestrant 250 mg + Loading Dose | — | 5/51 (9.8%) | 49/51 (96.1%) |
| Fulvestrant 500 mg | — | 1/46 (2.2%) | 44/46 (95.7%) |
| Event | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| Brain Stem InfarctionNervous system disorders | 1/45 | 0/51 | 0/46 |
| Herpes ZosterInfections and infestations | 1/45 | 0/51 | 0/46 |
| DizzinessNervous system disorders | 0/45 | 0/51 | 1/46 |
| Back PainMusculoskeletal and connective tissue disorders | 0/45 | 1/51 | 0/46 |
| Cardiac Failure CongestiveCardiac disorders | 0/45 | 1/51 | 0/46 |
| Diverticular PerforationGastrointestinal disorders | 0/45 | 1/51 | 0/46 |
| Fallopian Tube CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/45 | 1/51 | 0/46 |
| FibromaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/45 | 1/51 | 0/46 |
| Optic NeuritisNervous system disorders | 0/45 | 1/51 | 0/46 |
| Event | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 17/45 | 15/51 | 16/46 |
| Injection Site PainGeneral disorders | 14/45 | 11/51 | 14/46 |
| NauseaGastrointestinal disorders | 11/45 | 9/51 | 6/46 |
| Injection Site IndurationGeneral disorders | 9/45 | 6/51 | 10/46 |
| Hot FlushVascular disorders | 8/45 | 11/51 | 7/46 |
| HeadacheNervous system disorders | 3/45 | 8/51 | 4/46 |
| FatigueGeneral disorders | 7/45 | 7/51 | 7/46 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/45 | 7/51 | 2/46 |
| ConstipationGastrointestinal disorders | 4/45 | 7/51 | 5/46 |
| PyrexiaGeneral disorders | 2/45 | 4/51 | 5/46 |
| Age Continuous(Years) | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg | Total |
|---|---|---|---|---|
| Mean | 62.5 ± 7.4 | 62.4 ± 9.5 | 62.7 ± 9.1 | 62.5 ± 8.7 |
| Sex: Female, Male(Participants) | Fulvestrant 250 mg | Fulvestrant 250 mg + Loading Dose | Fulvestrant 500 mg | Total |
|---|---|---|---|---|
| Female | 45 | 51 | 47 | 143 |
| Male | 0 | 0 | 0 | 0 |
The record gives a start of Mar 2006, a primary completion of Mar 2008 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulvestrant